Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 49 of 49 entries
View as:

Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Phase: N/A Priority: Normal
NCT ID: NCT06476184 Org: User:
Start: 07/30/24 End: 12/31/28 Due: 12/31/29

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01069796 Org: User:
Start: 04/30/10 End: 06/30/14 Due: 06/30/15

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Phase: N/A Priority: Normal
NCT ID: NCT04602377 Org: User:
Start: 08/04/21 End: 02/28/30 Due: 02/28/31

Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

Phase: N/A Priority: Normal
NCT ID: NCT06599463 Org: User:
Start: 08/19/24 End: 02/28/25 Due: 02/28/26

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01303679 Org: User:
Start: 06/30/10 End: 05/31/18 Due: 05/31/19

COL Immunotherapy Before Radiochimio + Ipilimumab

Phase: N/A Priority: Normal
NCT ID: NCT04256213 Org: User:
Start: 07/02/20 End: 08/04/24 Due: 08/04/25

First Line Ovarian Cancer Treatment - Cohort Study

Phase: N/A Priority: Normal
NCT ID: NCT01832415 Org: User:
Start: 04/30/13 End: 03/31/16 Due: 03/31/17

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Phase: N/A Priority: Normal
NCT ID: NCT05201547 Org: User:
Start: 04/15/22 End: 10/31/29 Due: 10/31/30

French Observatory of Rare Malignant Tumors of the Ovary

Phase: N/A Priority: Normal
NCT ID: NCT01304043 Org: User:
Start: 01/31/02 End: 06/30/11 Due: 06/30/12

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

Phase: N/A Priority: Normal
NCT ID: NCT04152941 Org: User:
Start: 10/11/18 End: 02/11/20 Due: 02/11/21

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Phase: N/A Priority: Normal
NCT ID: NCT04713514 Org: User:
Start: 08/05/21 End: 12/31/25 Due: 12/31/26

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

Phase: N/A Priority: Normal
NCT ID: NCT01111903 Org: User:
Start: 05/31/09 End: 12/31/14 Due: 12/31/15

Genomic BRCA and Extensive ovArian Cancer Testing

Phase: N/A Priority: Normal
NCT ID: NCT04027868 Org: User:
Start: 12/06/19 End: 11/07/22 Due: 11/07/23

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Phase: N/A Priority: Normal
NCT ID: NCT00189566 Org: User:
Start: 04/30/04 End: 04/30/09 Due: 04/30/10

PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

Phase: N/A Priority: Normal
NCT ID: NCT03275506 Org: User:
Start: 02/26/18 End: 03/19/24 Due: 03/19/25

Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03579394 Org: User:
Start: 10/19/18 End: 07/31/28 Due: 07/31/29

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01298713 Org: User:
Start: 03/31/08 End: 09/12/18 Due: 09/12/19

A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Phase: N/A Priority: Normal
NCT ID: NCT06715241 Org: User:
Start: 12/11/24 End: 12/31/30 Due: 12/31/31

Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse

Phase: N/A Priority: Normal
NCT ID: NCT04015739 Org: User:
Start: 03/01/19 End: 01/29/24 Due: 01/29/25

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03249142 Org: User:
Start: 10/18/17 End: 12/31/24 Due: 12/31/25

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Phase: N/A Priority: Normal
NCT ID: NCT00189553 Org: User:
Start: 04/30/05 End: 06/30/12 Due: 06/30/13

The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00268840 Org: User:
Start: 08/31/01 End: 02/28/06 Due: 02/28/07

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00189579 Org: User:
Start: - End: 01/31/07 Due: 01/31/08

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06660147 Org: User:
Start: 12/11/23 End: 12/31/24 Due: 12/31/25